JP6820748B2 - Ｇｄｆ−１５を減少させるためのセレラキシンの使用 - Google Patents

Ｇｄｆ−１５を減少させるためのセレラキシンの使用 Download PDF

Info

Publication number
JP6820748B2
JP6820748B2 JP2016572697A JP2016572697A JP6820748B2 JP 6820748 B2 JP6820748 B2 JP 6820748B2 JP 2016572697 A JP2016572697 A JP 2016572697A JP 2016572697 A JP2016572697 A JP 2016572697A JP 6820748 B2 JP6820748 B2 JP 6820748B2
Authority
JP
Japan
Prior art keywords
celeraxin
gdf
patient
day
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016572697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519008A (ja
JP2017519008A5 (cg-RX-API-DMAC10.html
Inventor
フォーニー プリスコット，マーガレット
フォーニー プリスコット，マーガレット
ジャン，イーミン
ダールケ，マリオン
セヴェリン，トーマス
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017519008A publication Critical patent/JP2017519008A/ja
Publication of JP2017519008A5 publication Critical patent/JP2017519008A5/ja
Application granted granted Critical
Publication of JP6820748B2 publication Critical patent/JP6820748B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
JP2016572697A 2014-06-13 2015-06-10 Ｇｄｆ−１５を減少させるためのセレラキシンの使用 Expired - Fee Related JP6820748B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462011744P 2014-06-13 2014-06-13
US62/011,744 2014-06-13
PCT/IB2015/054399 WO2015189790A1 (en) 2014-06-13 2015-06-10 Use of serelaxin to reduce gdf-15

Publications (3)

Publication Number Publication Date
JP2017519008A JP2017519008A (ja) 2017-07-13
JP2017519008A5 JP2017519008A5 (cg-RX-API-DMAC10.html) 2018-07-19
JP6820748B2 true JP6820748B2 (ja) 2021-01-27

Family

ID=53476944

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572697A Expired - Fee Related JP6820748B2 (ja) 2014-06-13 2015-06-10 Ｇｄｆ−１５を減少させるためのセレラキシンの使用

Country Status (11)

Country Link
US (2) US20170100460A1 (cg-RX-API-DMAC10.html)
EP (1) EP3154559B1 (cg-RX-API-DMAC10.html)
JP (1) JP6820748B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170018829A (cg-RX-API-DMAC10.html)
CN (1) CN106413740A (cg-RX-API-DMAC10.html)
AU (2) AU2015273097A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016028833A2 (cg-RX-API-DMAC10.html)
CA (1) CA2952061A1 (cg-RX-API-DMAC10.html)
MX (1) MX2016016414A (cg-RX-API-DMAC10.html)
RU (1) RU2016147122A (cg-RX-API-DMAC10.html)
WO (1) WO2015189790A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
CN120919282A (zh) 2013-11-21 2025-11-11 布里格姆及妇女医院股份有限公司 用于治疗肺高压的组合物和方法
CN106794233B (zh) * 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
EP3988031A4 (en) * 2019-06-20 2022-08-10 Sony Group Corporation Information processing device, information processing method, and program

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101245877B1 (ko) * 2006-08-04 2013-03-20 메디치니쉐 호흐슐레 하노버 Ｇｄｆ-15 를 바탕으로 한, 심장 중재의 위험도를 평가하는수단 및 방법
ES2379104T3 (es) * 2007-05-24 2012-04-20 F. Hoffmann-La Roche Ag Métodos para evaluar el fallo cardíaco en pacientes con fibrilación auricular utilizando péptidos GDF-15
US8415301B2 (en) * 2008-05-16 2013-04-09 Corthera, Inc. Method of treating dyspnea associated with acute heart failure by administering H2 relaxin
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
JP2017519008A (ja) 2017-07-13
BR112016028833A2 (pt) 2017-08-22
CN106413740A (zh) 2017-02-15
CA2952061A1 (en) 2015-12-17
KR20170018829A (ko) 2017-02-20
AU2018202289A1 (en) 2018-04-26
RU2016147122A (ru) 2018-07-16
US20190022189A1 (en) 2019-01-24
RU2016147122A3 (cg-RX-API-DMAC10.html) 2019-01-28
EP3154559B1 (en) 2021-09-01
AU2015273097A1 (en) 2016-11-17
MX2016016414A (es) 2017-04-10
WO2015189790A1 (en) 2015-12-17
EP3154559A1 (en) 2017-04-19
US20170100460A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
US20190022189A1 (en) Use of serelaxin to reduce gdf-15
Yilmaz et al. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease
EP2885641B1 (en) Methods for predicting risk of developing hypertension
Marcus et al. Intracardiac and extracardiac markers of inflammation during atrial fibrillation
Navarro-Sobrino et al. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke
Berezin et al. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease
Nakazato et al. Association of calciprotein particles measured by a new method with coronary artery plaque in patients with coronary artery disease: a cross-sectional study
Kadoglou et al. Adipokines: a novel link between adiposity and carotid plaque vulnerability
DK2288373T3 (en) RELAXIN FOR USE IN A PROCESS FOR THE TREATMENT OF dyspnea ASSOCIATED WITH HJERTEISSUFICIENS
Fukami et al. Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population
Seo et al. Presence of carotid plaque is associated with rapid renal function decline in patients with type 2 diabetes mellitus and normal renal function
Mapelli et al. Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?
Domenech et al. High risk of subclinical atherosclerosis in COPD exacerbator phenotype
Bitto et al. High mobility group box-1 expression correlates with poor outcome in lung injury patients
Boussir et al. Eosinophilic myocarditis and hypereosinophilic syndrome
Ranjith et al. Prognostic value of N-terminal-pro-brain natriuretic peptide measurements in patients with acute coronary syndromes: cardiovascular topic
Dominguez-Rodriguez et al. Elevated circulating soluble form of CD40 ligand in patients with cardiac syndrome X
Iacobellis et al. High circulating vascular endothelial growth factor (VEGF) is related to a better systolic function in diabetic hypertensive patients
Cami et al. Comorbidity-Driven Inflammation in HFpEF: Immune Profiling and Therapeutic Targets
Ceyhan Epicardial fat thickness in patients with gestational diabetes mellitus and its association with N-terminal pro-brain natriuretic peptide.
Akkaya Meteorin-like Protein (Metrnl) and Coronary Collateral Circulation in Patients with Chronic Total Occlusion: A Prospective Observational Study
GEORGOPOULOU 1ST DEPARTMENT OF UNIVERSITY CARDIOLOGY CLINIC & HOMONYM LABORATORY OF
Shpagin et al. P3486 Cytokine profile, renin-angiotensin aldosterone system and left ventricular remodelling in essential arterial hypertension comorbid with chronic obstructive pulmonary disease
BA BEST ABSTRACTS SITZUNG
Carvalho et al. Pericardial fat volume measured by non-contrast tomography improves risk prediction of subclinical coronary artery disease estimated by coronary artery calcium score and Framinghan risk score

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180604

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190226

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210105

R150 Certificate of patent or registration of utility model

Ref document number: 6820748

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees